Trial Profile
Assessment of the immunogenicity and safety of the Northern Hemisphere 2009/2010-season influenza vaccine in elderly and young subjects according to European Medicines Agency (EMEA) regulations.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine liposomal (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Crucell
- 28 Feb 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health, NCT01306253).
- 31 Aug 2009 Status changed from unconfirmed to completed as reported by ISRCTN: Current Controlled Trials.
- 03 Jun 2009 New trial record